Click for best price
Urological Cancer Drugs Market Size, Share 2023
This report aims to provide a comprehensive presentation of the global market for Urological Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Urological Cancer Drugs. This report contains market size and forecasts of Urological Cancer Drugs in global, including the following market information:
Global Urological Cancer Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Urological Cancer Drugs Market Sales, 2018-2023, 2024-2029, (K Pcs)
Global top five Urological Cancer Drugs companies in 2022 (%)
The global Urological Cancer Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Tablets Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Urological Cancer Drugs include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation and Dendreon Corporation, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Urological Cancer Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Urological Cancer Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Urological Cancer Drugs Market Segment Percentages, by Type, 2022 (%)
Tablets
Injection
Global Urological Cancer Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Urological Cancer Drugs Market Segment Percentages, by Application, 2022 (%)
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Others
Global Urological Cancer Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Urological Cancer Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Urological Cancer Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Urological Cancer Drugs revenues share in global market, 2022 (%)
Key companies Urological Cancer Drugs sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Urological Cancer Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A
Tolmar Inc
Outline of Major Chapters:
Chapter 1: Introduces the definition of Urological Cancer Drugs, market overview.
Chapter 2: Global Urological Cancer Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Urological Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Urological Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Urological Cancer Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Urological Cancer Drugs Market, Global Outlook and Forecast 2023-2029 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
112 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Urological Cancer Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Urological Cancer Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Urological Cancer Drugs Overall Market Size
2.1 Global Urological Cancer Drugs Market Size: 2022 VS 2029
2.2 Global Urological Cancer Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Urological Cancer Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Urological Cancer Drugs Players in Global Market
3.2 Top Global Urological Cancer Drugs Companies Ranked by Revenue
3.3 Global Urological Cancer Drugs Revenue by Companies
3.4 Global Urological Cancer Drugs Sales by Companies
3.5 Global Urological Cancer Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Urological Cancer Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Urological Cancer Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Urological Cancer Drugs Players in Global Market
3.8.1 List of Global Tier 1 Urological Cancer Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Urological Cancer Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Urological Cancer Drugs Market Size Markets, 2022 & 2029
4.1.2 Tablets
4.1.3 Injection
4.2 By Type - Global Urological Cancer Drugs Revenue & Forecasts
4.2.1 By Type - Global Urological Cancer Drugs Revenue, 2018-2023
4.2.2 By Type - Global Urological Cancer Drugs Revenue, 2024-2029
4.2.3 By Type - Global Urological Cancer Drugs Revenue Market Share, 2018-2029
4.3 By Type - Global Urological Cancer Drugs Sales & Forecasts
4.3.1 By Type - Global Urological Cancer Drugs Sales, 2018-2023
4.3.2 By Type - Global Urological Cancer Drugs Sales, 2024-2029
4.3.3 By Type - Global Urological Cancer Drugs Sales Market Share, 2018-2029
4.4 By Type - Global Urological Cancer Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Urological Cancer Drugs Market Size, 2022 & 2029
5.1.2 Prostate Cancer
5.1.3 Bladder Cancer
5.1.4 Kidney Cancer
5.1.5 Testicular Cancer
5.1.6 Others
5.2 By Application - Global Urological Cancer Drugs Revenue & Forecasts
5.2.1 By Application - Global Urological Cancer Drugs Revenue, 2018-2023
5.2.2 By Application - Global Urological Cancer Drugs Revenue, 2024-2029
5.2.3 By Application - Global Urological Cancer Drugs Revenue Market Share, 2018-2029
5.3 By Application - Global Urological Cancer Drugs Sales & Forecasts
5.3.1 By Application - Global Urological Cancer Drugs Sales, 2018-2023
5.3.2 By Application - Global Urological Cancer Drugs Sales, 2024-2029
5.3.3 By Application - Global Urological Cancer Drugs Sales Market Share, 2018-2029
5.4 By Application - Global Urological Cancer Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Urological Cancer Drugs Market Size, 2022 & 2029
6.2 By Region - Global Urological Cancer Drugs Revenue & Forecasts
6.2.1 By Region - Global Urological Cancer Drugs Revenue, 2018-2023
6.2.2 By Region - Global Urological Cancer Drugs Revenue, 2024-2029
6.2.3 By Region - Global Urological Cancer Drugs Revenue Market Share, 2018-2029
6.3 By Region - Global Urological Cancer Drugs Sales & Forecasts
6.3.1 By Region - Global Urological Cancer Drugs Sales, 2018-2023
6.3.2 By Region - Global Urological Cancer Drugs Sales, 2024-2029
6.3.3 By Region - Global Urological Cancer Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Urological Cancer Drugs Revenue, 2018-2029
6.4.2 By Country - North America Urological Cancer Drugs Sales, 2018-2029
6.4.3 US Urological Cancer Drugs Market Size, 2018-2029
6.4.4 Canada Urological Cancer Drugs Market Size, 2018-2029
6.4.5 Mexico Urological Cancer Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Urological Cancer Drugs Revenue, 2018-2029
6.5.2 By Country - Europe Urological Cancer Drugs Sales, 2018-2029
6.5.3 Germany Urological Cancer Drugs Market Size, 2018-2029
6.5.4 France Urological Cancer Drugs Market Size, 2018-2029
6.5.5 U.K. Urological Cancer Drugs Market Size, 2018-2029
6.5.6 Italy Urological Cancer Drugs Market Size, 2018-2029
6.5.7 Russia Urological Cancer Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Urological Cancer Drugs Market Size, 2018-2029
6.5.9 Benelux Urological Cancer Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Urological Cancer Drugs Revenue, 2018-2029
6.6.2 By Region - Asia Urological Cancer Drugs Sales, 2018-2029
6.6.3 China Urological Cancer Drugs Market Size, 2018-2029
6.6.4 Japan Urological Cancer Drugs Market Size, 2018-2029
6.6.5 South Korea Urological Cancer Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Urological Cancer Drugs Market Size, 2018-2029
6.6.7 India Urological Cancer Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Urological Cancer Drugs Revenue, 2018-2029
6.7.2 By Country - South America Urological Cancer Drugs Sales, 2018-2029
6.7.3 Brazil Urological Cancer Drugs Market Size, 2018-2029
6.7.4 Argentina Urological Cancer Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Urological Cancer Drugs Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Urological Cancer Drugs Sales, 2018-2029
6.8.3 Turkey Urological Cancer Drugs Market Size, 2018-2029
6.8.4 Israel Urological Cancer Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Urological Cancer Drugs Market Size, 2018-2029
6.8.6 UAE Urological Cancer Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Novartis
7.1.1 Novartis Company Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis Urological Cancer Drugs Major Product Offerings
7.1.4 Novartis Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Novartis Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Urological Cancer Drugs Major Product Offerings
7.2.4 Pfizer Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Pfizer Key News & Latest Developments
7.3 Johnson & Johnson
7.3.1 Johnson & Johnson Company Summary
7.3.2 Johnson & Johnson Business Overview
7.3.3 Johnson & Johnson Urological Cancer Drugs Major Product Offerings
7.3.4 Johnson & Johnson Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Johnson & Johnson Key News & Latest Developments
7.4 AstraZeneca
7.4.1 AstraZeneca Company Summary
7.4.2 AstraZeneca Business Overview
7.4.3 AstraZeneca Urological Cancer Drugs Major Product Offerings
7.4.4 AstraZeneca Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.4.5 AstraZeneca Key News & Latest Developments
7.5 Astellas
7.5.1 Astellas Company Summary
7.5.2 Astellas Business Overview
7.5.3 Astellas Urological Cancer Drugs Major Product Offerings
7.5.4 Astellas Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Astellas Key News & Latest Developments
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Company Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Urological Cancer Drugs Major Product Offerings
7.6.4 Bristol-Myers Squibb Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Bristol-Myers Squibb Key News & Latest Developments
7.7 Abbott Laboratories
7.7.1 Abbott Laboratories Company Summary
7.7.2 Abbott Laboratories Business Overview
7.7.3 Abbott Laboratories Urological Cancer Drugs Major Product Offerings
7.7.4 Abbott Laboratories Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Abbott Laboratories Key News & Latest Developments
7.8 Celgene Corporation
7.8.1 Celgene Corporation Company Summary
7.8.2 Celgene Corporation Business Overview
7.8.3 Celgene Corporation Urological Cancer Drugs Major Product Offerings
7.8.4 Celgene Corporation Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Celgene Corporation Key News & Latest Developments
7.9 Dendreon Corporation
7.9.1 Dendreon Corporation Company Summary
7.9.2 Dendreon Corporation Business Overview
7.9.3 Dendreon Corporation Urological Cancer Drugs Major Product Offerings
7.9.4 Dendreon Corporation Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Dendreon Corporation Key News & Latest Developments
7.10 Ferring Pharmaceuticals
7.10.1 Ferring Pharmaceuticals Company Summary
7.10.2 Ferring Pharmaceuticals Business Overview
7.10.3 Ferring Pharmaceuticals Urological Cancer Drugs Major Product Offerings
7.10.4 Ferring Pharmaceuticals Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Ferring Pharmaceuticals Key News & Latest Developments
7.11 GlaxoSmithKline
7.11.1 GlaxoSmithKline Company Summary
7.11.2 GlaxoSmithKline Urological Cancer Drugs Business Overview
7.11.3 GlaxoSmithKline Urological Cancer Drugs Major Product Offerings
7.11.4 GlaxoSmithKline Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.11.5 GlaxoSmithKline Key News & Latest Developments
7.12 Indevus Pharmaceuticals Inc
7.12.1 Indevus Pharmaceuticals Inc Company Summary
7.12.2 Indevus Pharmaceuticals Inc Urological Cancer Drugs Business Overview
7.12.3 Indevus Pharmaceuticals Inc Urological Cancer Drugs Major Product Offerings
7.12.4 Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.12.5 Indevus Pharmaceuticals Inc Key News & Latest Developments
7.13 Ipsen
7.13.1 Ipsen Company Summary
7.13.2 Ipsen Urological Cancer Drugs Business Overview
7.13.3 Ipsen Urological Cancer Drugs Major Product Offerings
7.13.4 Ipsen Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.13.5 Ipsen Key News & Latest Developments
7.14 Roche Healthcare
7.14.1 Roche Healthcare Company Summary
7.14.2 Roche Healthcare Business Overview
7.14.3 Roche Healthcare Urological Cancer Drugs Major Product Offerings
7.14.4 Roche Healthcare Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.14.5 Roche Healthcare Key News & Latest Developments
7.15 Sanofi S.A
7.15.1 Sanofi S.A Company Summary
7.15.2 Sanofi S.A Business Overview
7.15.3 Sanofi S.A Urological Cancer Drugs Major Product Offerings
7.15.4 Sanofi S.A Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.15.5 Sanofi S.A Key News & Latest Developments
7.16 Tolmar Inc
7.16.1 Tolmar Inc Company Summary
7.16.2 Tolmar Inc Business Overview
7.16.3 Tolmar Inc Urological Cancer Drugs Major Product Offerings
7.16.4 Tolmar Inc Urological Cancer Drugs Sales and Revenue in Global (2018-2023)
7.16.5 Tolmar Inc Key News & Latest Developments
8 Global Urological Cancer Drugs Production Capacity, Analysis
8.1 Global Urological Cancer Drugs Production Capacity, 2018-2029
8.2 Urological Cancer Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Urological Cancer Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Urological Cancer Drugs Supply Chain Analysis
10.1 Urological Cancer Drugs Industry Value Chain
10.2 Urological Cancer Drugs Upstream Market
10.3 Urological Cancer Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Urological Cancer Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Urological Cancer Drugs in Global Market
Table 2. Top Urological Cancer Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Urological Cancer Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Urological Cancer Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Urological Cancer Drugs Sales by Companies, (K Pcs), 2018-2023
Table 6. Global Urological Cancer Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Urological Cancer Drugs Price (2018-2023) & (USD/Pcs)
Table 8. Global Manufacturers Urological Cancer Drugs Product Type
Table 9. List of Global Tier 1 Urological Cancer Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Urological Cancer Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Urological Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Urological Cancer Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Urological Cancer Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Urological Cancer Drugs Sales (K Pcs), 2018-2023
Table 15. By Type - Global Urological Cancer Drugs Sales (K Pcs), 2024-2029
Table 16. By Application ? Global Urological Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Urological Cancer Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Urological Cancer Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Urological Cancer Drugs Sales (K Pcs), 2018-2023
Table 20. By Application - Global Urological Cancer Drugs Sales (K Pcs), 2024-2029
Table 21. By Region ? Global Urological Cancer Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Urological Cancer Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Urological Cancer Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Urological Cancer Drugs Sales (K Pcs), 2018-2023
Table 25. By Region - Global Urological Cancer Drugs Sales (K Pcs), 2024-2029
Table 26. By Country - North America Urological Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Urological Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Urological Cancer Drugs Sales, (K Pcs), 2018-2023
Table 29. By Country - North America Urological Cancer Drugs Sales, (K Pcs), 2024-2029
Table 30. By Country - Europe Urological Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Urological Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Urological Cancer Drugs Sales, (K Pcs), 2018-2023
Table 33. By Country - Europe Urological Cancer Drugs Sales, (K Pcs), 2024-2029
Table 34. By Region - Asia Urological Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Urological Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Urological Cancer Drugs Sales, (K Pcs), 2018-2023
Table 37. By Region - Asia Urological Cancer Drugs Sales, (K Pcs), 2024-2029
Table 38. By Country - South America Urological Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Urological Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Urological Cancer Drugs Sales, (K Pcs), 2018-2023
Table 41. By Country - South America Urological Cancer Drugs Sales, (K Pcs), 2024-2029
Table 42. By Country - Middle East & Africa Urological Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Urological Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Urological Cancer Drugs Sales, (K Pcs), 2018-2023
Table 45. By Country - Middle East & Africa Urological Cancer Drugs Sales, (K Pcs), 2024-2029
Table 46. Novartis Company Summary
Table 47. Novartis Urological Cancer Drugs Product Offerings
Table 48. Novartis Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 49. Novartis Key News & Latest Developments
Table 50. Pfizer Company Summary
Table 51. Pfizer Urological Cancer Drugs Product Offerings
Table 52. Pfizer Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 53. Pfizer Key News & Latest Developments
Table 54. Johnson & Johnson Company Summary
Table 55. Johnson & Johnson Urological Cancer Drugs Product Offerings
Table 56. Johnson & Johnson Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 57. Johnson & Johnson Key News & Latest Developments
Table 58. AstraZeneca Company Summary
Table 59. AstraZeneca Urological Cancer Drugs Product Offerings
Table 60. AstraZeneca Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 61. AstraZeneca Key News & Latest Developments
Table 62. Astellas Company Summary
Table 63. Astellas Urological Cancer Drugs Product Offerings
Table 64. Astellas Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 65. Astellas Key News & Latest Developments
Table 66. Bristol-Myers Squibb Company Summary
Table 67. Bristol-Myers Squibb Urological Cancer Drugs Product Offerings
Table 68. Bristol-Myers Squibb Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 69. Bristol-Myers Squibb Key News & Latest Developments
Table 70. Abbott Laboratories Company Summary
Table 71. Abbott Laboratories Urological Cancer Drugs Product Offerings
Table 72. Abbott Laboratories Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 73. Abbott Laboratories Key News & Latest Developments
Table 74. Celgene Corporation Company Summary
Table 75. Celgene Corporation Urological Cancer Drugs Product Offerings
Table 76. Celgene Corporation Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 77. Celgene Corporation Key News & Latest Developments
Table 78. Dendreon Corporation Company Summary
Table 79. Dendreon Corporation Urological Cancer Drugs Product Offerings
Table 80. Dendreon Corporation Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 81. Dendreon Corporation Key News & Latest Developments
Table 82. Ferring Pharmaceuticals Company Summary
Table 83. Ferring Pharmaceuticals Urological Cancer Drugs Product Offerings
Table 84. Ferring Pharmaceuticals Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 85. Ferring Pharmaceuticals Key News & Latest Developments
Table 86. GlaxoSmithKline Company Summary
Table 87. GlaxoSmithKline Urological Cancer Drugs Product Offerings
Table 88. GlaxoSmithKline Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 89. GlaxoSmithKline Key News & Latest Developments
Table 90. Indevus Pharmaceuticals Inc Company Summary
Table 91. Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Offerings
Table 92. Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 93. Indevus Pharmaceuticals Inc Key News & Latest Developments
Table 94. Ipsen Company Summary
Table 95. Ipsen Urological Cancer Drugs Product Offerings
Table 96. Ipsen Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 97. Ipsen Key News & Latest Developments
Table 98. Roche Healthcare Company Summary
Table 99. Roche Healthcare Urological Cancer Drugs Product Offerings
Table 100. Roche Healthcare Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 101. Roche Healthcare Key News & Latest Developments
Table 102. Sanofi S.A Company Summary
Table 103. Sanofi S.A Urological Cancer Drugs Product Offerings
Table 104. Sanofi S.A Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 105. Sanofi S.A Key News & Latest Developments
Table 106. Tolmar Inc Company Summary
Table 107. Tolmar Inc Urological Cancer Drugs Product Offerings
Table 108. Tolmar Inc Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 109. Tolmar Inc Key News & Latest Developments
Table 110. Urological Cancer Drugs Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2021-2023 (K Pcs)
Table 111. Global Urological Cancer Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 112. Global Urological Cancer Drugs Production by Region, 2018-2023 (K Pcs)
Table 113. Global Urological Cancer Drugs Production by Region, 2024-2029 (K Pcs)
Table 114. Urological Cancer Drugs Market Opportunities & Trends in Global Market
Table 115. Urological Cancer Drugs Market Drivers in Global Market
Table 116. Urological Cancer Drugs Market Restraints in Global Market
Table 117. Urological Cancer Drugs Raw Materials
Table 118. Urological Cancer Drugs Raw Materials Suppliers in Global Market
Table 119. Typical Urological Cancer Drugs Downstream
Table 120. Urological Cancer Drugs Downstream Clients in Global Market
Table 121. Urological Cancer Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Urological Cancer Drugs Segment by Type in 2022
Figure 2. Urological Cancer Drugs Segment by Application in 2022
Figure 3. Global Urological Cancer Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Urological Cancer Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Urological Cancer Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Urological Cancer Drugs Sales in Global Market: 2018-2029 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Urological Cancer Drugs Revenue in 2022
Figure 9. By Type - Global Urological Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Urological Cancer Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Urological Cancer Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Urological Cancer Drugs Price (USD/Pcs), 2018-2029
Figure 13. By Application - Global Urological Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Urological Cancer Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Urological Cancer Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Urological Cancer Drugs Price (USD/Pcs), 2018-2029
Figure 17. By Region - Global Urological Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Urological Cancer Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Urological Cancer Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Urological Cancer Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Urological Cancer Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Urological Cancer Drugs Sales Market Share, 2018-2029
Figure 23. US Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Urological Cancer Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Urological Cancer Drugs Sales Market Share, 2018-2029
Figure 28. Germany Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Urological Cancer Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Urological Cancer Drugs Sales Market Share, 2018-2029
Figure 37. China Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Urological Cancer Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Urological Cancer Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Urological Cancer Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Urological Cancer Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Urological Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Urological Cancer Drugs Production Capacity (K Pcs), 2018-2029
Figure 53. The Percentage of Production Urological Cancer Drugs by Region, 2022 VS 2029
Figure 54. Urological Cancer Drugs Industry Value Chain
Figure 55. Marketing Channels
